Ultragenyx Pharma v. Navinta 2:26-cv-03585: Litigation Summary, Claims, and Business Impact
Executive summary: The case Ultragenyx Pharmaceutical Inc. v. Navinta LLC, No. 2:26-cv-03585 (filed 2026) is a patent infringement dispute tied to generic or biosimilar-style market entry pressures. The docket number indicates a federal IP case in the District of New Jersey. A complete litigation summary (claims, asserted patents, procedures, and status) cannot be produced from the information provided.
What patents are asserted in Ultragenyx Pharma v. Navinta LLC 2:26-cv-03585?
A litigation summary depends on the asserted patent list contained in the complaint, initial disclosures, or early scheduling orders. With only the case caption and docket number provided, the asserted patents, assignees, and claim numbers are not determinable.
Which patent numbers are listed in the complaint
Not available from the provided input.
Are the asserted patents Orange Book listed patents or other IP
Not available from the provided input.
What is the procedural posture in 2:26-cv-03585 (filed, answered, Markman, injunction, discovery)?
A credible posture requires docket events and dates (e.g., Rule 16…
